Table 3.
Hemodynamics and clinical parameters of the patients with a lipase serum activity >180 U/l (GGT: gamma-glutamyltransferase; AP: alkaline phosphatase; CRP: C-reactive protein; MAP: mean arterial pressure; GEDVI: global end-diastolic volume index; SVV: stroke volume variation).
| Laboratory findings | reference range | unit | |
|---|---|---|---|
| highest serum lipase activity | 13–60 | U/l | 422 (186–1127) |
| onset of symptoms to highest lipase level | days | 16.1 ± 6.0 | |
| highest CRP level | <0.5 | mg/dl | 33.0 ± 8.9 |
| hematocrit at highest lipase activity | % | 31.1 ± 4.6 | |
| Physical examination | |||
| abdominal tenderness and guarding | 2/12 (16.7%) | ||
| Imaging | |||
| Computed tomography - with contrast |
4/12 (33.3%) 3/12 (25%) |
||
| Abdominal Ultrasound | 10/12 (83.3%) | ||
| Signs of pancreatitis | 0/12 (0%) | ||
| Choledocholithiasis | 0/12 (0%) | ||
| Dilated biliary duct | 0/12 (0%) | ||
| Hemodynamic monitoring | |||
| at highest lipase activity | MAP | mmHg | 84 ± 8.6 |
| Therapy with vasopressors | 5/12 (41.7%) | ||
| Noradrenalin dose (μg/h) | 167 (0–800) | ||
| GEDVI | 822 (635–1279) | ||
| Volume expansion with crystalloids | 0/12 (0%) | ||
| 24 h after highest lipase activity | MAP | mmHg | 89 ± 16.6 |
| Therapy with vasopressors | 6/12 (50%) | ||
| Noradrenalin dose (μg/h) | 148 (0–800) | ||
| GEDVI | 11/12 | 806 ± 162 | |